Mark Sayles

Mark Sayles currently serves as a Clinical Development Consultant at TCG Labs Soleil, beginning in January 2024. Previously, from January 2023 to November 2024, Mark held the position of Executive Medical Director for Oncology Clinical Development at Asher Biotherapeutics, where notable projects included the development of AB248 and AB821 for solid tumors. Prior to that, Mark was Executive Medical Director at Harpoon Therapeutics from August 2021 to January 2023, focusing on HPN328 and HPN601. Mark's experience also includes a role as Medical Director for Oncology Clinical Development at Amgen, as well as several academic and research positions at Purdue University and KU Leuven. Mark earned a Doctor of Medicine, a Doctor of Philosophy, and multiple degrees from the University of Cambridge.